The United States spends more on prescription drugs than any other country, yet a federal program created over three decades ago continues to deliver significant relief for safety-net providers and their patients. The 340B Drug Pricing Program requires pharmaceutical manufacturers to sell outpatient drugs at steep discounts to eligible healthcare organizations, stretching scarce federal resources and expanding access to care. Understanding how this program works can help you access medications at prices far below retail.
Origins and Purpose of the 340B Drug Pricing Program
Congress established the 340B Drug Pricing Program in 1992 as part of the Veterans Health Care Act. The law, codified in Section 340B of the Public Health Service Act, was designed to help safety-net providers serve low-income and uninsured patients. By requiring manufacturers to offer discounted prices, the program allows these providers to stretch limited budgets and offer more comprehensive care.
The Health Resources and Services Administration (HRSA) administers the program. According to HRSA data, more than 50,000 covered entity sites now participate in 340B, purchasing an estimated $53 billion in discounted drugs annually. The program has grown substantially since its inception, reflecting both expanding eligibility criteria and rising drug costs.
How 340B Pricing Works
Drug manufacturers that participate in Medicaid must also participate in 340B. They are required to sell covered outpatient drugs to eligible healthcare organizations at or below the 340B ceiling price. This ceiling price is calculated as the Average Manufacturer Price (AMP) minus the Unit Rebate Amount (URA), the same rebate formula used for Medicaid but applied as a direct discount at the point of purchase.
The resulting discounts typically range from 25% to 50% off wholesale acquisition cost. For certain drugs, especially brand-name specialty medications, discounts can exceed 80%. HRSA calculates and publishes ceiling prices through its 340B Office of Pharmacy Affairs Pricing System (OPAIS), though these prices are confidential and not publicly disclosed to prevent market manipulation.
Eligible Covered Entities
Not every healthcare provider can participate in the 340B Drug Pricing Program. Eligible covered entities include Federally Qualified Health Centers (FQHCs) and FQHC Look-Alikes, Ryan White HIV/AIDS Program grantees, disproportionate share hospitals (DSH hospitals with a DSH adjustment percentage above 11.75%), children’s hospitals exempt from Medicare prospective payment, critical access hospitals, sole community hospitals, rural referral centers, free-standing cancer hospitals, and certain specialized clinics.
Each entity must register with HRSA and comply with program requirements, including maintaining auditable records of 340B purchases and dispensing. Covered entities can operate their own in-house pharmacies or contract with outside retail pharmacies to dispense 340B drugs to eligible patients. For information on filling prescriptions at these pharmacies, see our 340B pharmacy guide.
How Patients Benefit
The 340B program benefits patients in two primary ways. First, some covered entities pass discounted drug prices directly to patients. Community health centers, for example, often operate sliding-fee-scale pharmacies where 340B-priced medications are available to patients based on their ability to pay. An uninsured patient at an FQHC might pay $10 for a generic medication that costs $40 at a retail pharmacy.
Second, even when discounts are not passed through at the pharmacy counter, covered entities reinvest 340B savings into expanded services. This can include free or reduced-cost primary care visits, dental services, behavioral health programs, chronic disease management, and patient navigation services. HRSA requires that covered entities use 340B savings to benefit their patient populations, though the agency allows flexibility in how benefits are distributed.
340B and Insurance: How They Interact
Patients with insurance, including Medicare Part D and commercial plans, can fill prescriptions through 340B covered entities. When an insured patient fills a prescription at a 340B pharmacy, the insurance plan pays its usual reimbursement, and the covered entity purchases the drug at the 340B price. The difference between the reimbursement and the purchase price generates revenue that the entity reinvests in patient care.
In this scenario, the patient typically pays their standard copay or coinsurance. The direct financial benefit goes to the covered entity rather than the patient at the point of sale. However, the indirect benefit is significant: the revenue supports services that reduce overall healthcare costs for the community. For insured patients seeking direct out-of-pocket savings, prescription discount cards or Medicare Extra Help may be more immediately impactful.
Growth and Controversy
The 340B program has expanded dramatically since its creation. The number of covered entity sites grew from roughly 8,000 in 2005 to over 50,000 today. 340B purchases now account for an estimated 10% of all U.S. drug purchases by revenue. This growth has attracted scrutiny from multiple stakeholders.
Pharmaceutical manufacturers argue that the program has expanded beyond its original intent, with large hospital systems generating significant 340B revenue while not always directing savings to low-income patients. A 2020 study in the New England Journal of Medicine found that 340B hospitals did not consistently provide more charity care than non-340B hospitals. In response, several manufacturers have restricted 340B pricing at contract pharmacies, leading to ongoing litigation.
Patient advocacy groups and safety-net providers counter that the program remains essential for funding care in underserved communities. They argue that restricting 340B pricing would force health centers and hospitals to cut services that vulnerable populations depend on. HRSA has proposed additional oversight measures, including requiring covered entities to report on how 340B savings are used, though comprehensive reform legislation has stalled in Congress.
Navigating the Program as a Patient
If you want to take advantage of the 340B Drug Pricing Program, start by determining whether you receive care at a covered entity. The HRSA OPAIS database at HRSA.gov/opa lets you search for registered entities by location. Federally Qualified Health Centers are the most accessible entry point, as they accept patients regardless of insurance status and often charge on a sliding scale.
Once you are a patient at a covered entity, ask about their pharmacy services. Some entities have on-site pharmacies with direct 340B pricing. Others work with contract pharmacies, though availability varies by location and manufacturer. If your covered entity does not offer direct drug discounts, the expanded services funded by 340B savings still benefit you through lower-cost care. Combine 340B access with State Pharmaceutical Assistance Programs and manufacturer programs like those from Novo Nordisk for comprehensive savings.
Frequently Asked Questions
Is the 340B Drug Pricing Program the same as Medicaid drug pricing?
No, though the pricing formulas are related. Both use the Average Manufacturer Price and the Medicaid rebate amount to determine pricing, but the mechanisms differ. Medicaid collects rebates after the sale, while 340B applies the discount at the point of purchase. The 340B Drug Pricing Program is separate from Medicaid, though manufacturers must participate in both.
Can I use 340B if I have commercial insurance?
Yes. Patients with commercial insurance can fill prescriptions through 340B covered entities. Your insurance plan pays its normal rate, and the covered entity benefits from the lower acquisition cost. You pay your standard copay or coinsurance at the pharmacy.
How much can I save with 340B pricing?
Direct savings for patients vary by covered entity. At FQHCs with sliding-fee-scale pharmacies, uninsured patients can save 50% to 90% compared to retail pricing. Insured patients benefit indirectly through expanded services. Specific savings depend on the medication, your coverage, and the covered entity’s policies.
Does 340B cover specialty drugs?
Yes. The 340B program covers all FDA-approved outpatient drugs from participating manufacturers, including expensive specialty medications for conditions like cancer, HIV, hepatitis C, and autoimmune diseases. Specialty drugs often see the largest percentage discounts under 340B, as the spread between retail price and 340B ceiling price is greatest for high-cost medications.
Leverage 340B for Better Affordability
The 340B Drug Pricing Program is a powerful but often misunderstood resource. Whether you benefit from direct drug discounts at a community health center or from the expanded services that 340B revenue funds, the program plays a meaningful role in making healthcare more affordable. Explore the HRSA database to find covered entities near you, and visit our healthcare costs guide for additional strategies to manage your prescription spending.